Favorable Press Coverage Somewhat Unlikely to Impact Axsome Therapeutics (AXSM) Share Price

Media headlines about Axsome Therapeutics (NASDAQ:AXSM) have been trending positive on Saturday, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Axsome Therapeutics earned a news sentiment score of 0.25 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.2387939720068 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:

AXSM has been the subject of a number of research reports. Zacks Investment Research lowered shares of Axsome Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 22nd. Cantor Fitzgerald set a $13.00 price objective on shares of Axsome Therapeutics and gave the stock a “buy” rating in a research note on Friday, December 1st. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Axsome Therapeutics has a consensus rating of “Buy” and a consensus target price of $16.90.

Axsome Therapeutics (NASDAQ:AXSM) traded down $0.10 during trading hours on Friday, reaching $3.30. 1,342,047 shares of the company were exchanged, compared to its average volume of 539,181. Axsome Therapeutics has a 52 week low of $3.10 and a 52 week high of $6.45. The stock has a market capitalization of $83.98 and a price-to-earnings ratio of -2.43. The company has a current ratio of 3.86, a quick ratio of 3.86 and a debt-to-equity ratio of 0.44.

WARNING: “Favorable Press Coverage Somewhat Unlikely to Impact Axsome Therapeutics (AXSM) Share Price” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2018/01/13/favorable-press-coverage-somewhat-unlikely-to-impact-axsome-therapeutics-axsm-share-price.html.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.

Insider Buying and Selling by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply